
Amyotrophic Lateral Sclerosis- Pipeline Insight, 2025
Description
DelveInsight’s, “Amyotrophic Lateral Sclerosis- Pipeline Insight, 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Amyotrophic Lateral Sclerosis: Overview
Amyotrophic Lateral Sclerosis, also known as “Lou Gehrig disease,” is a neurodegenerative disease of the motor neurons. No single etiology has been proven; rather, multiple pathways (both heritable and sporadic) have been shown to result in unmistakably similar disease entities. ALS necessarily affects both upper and lower motor neurons with variable patterns of onset, most commonly beginning with signs of lower motor neuron degeneration within proximal limbs. As it is a progressive disease, it will eventually lead to paralysis and, inevitably, death.
Although many potential mechanisms have been proposed, a precise, single etiology of sporadic amyotrophic lateral sclerosis is yet unproven. These mechanisms include altered RNA processing leading to prion-like self-aggregation, superoxide dismutase type 1 SOD1 mutations leading to free radical toxicity, cascading inflammatory responses, and excessive concentrations of glutamate, among others. The rarer entity of familial ALS has numerous genetic mechanisms, most frequently repeat expansion of the C9ORF72 gene and various mutations of the SOD1 gene. Mutated SOD1 protein misfold and forms aggregates, leading to cellular injury and eventually apoptosis. Both genetic aberrations are inherited in a mainly autosomal dominant pattern. Ultimately, rather than a single unifying cause, ALS is an etiologically diverse clinical entity, which is the result of a multitude of separate potential preceding aberrations.
Respiratory management is crucial, as ALS patients often develop chronic respiratory failure due to weakening of the diaphragmatic and intercostal muscles. Noninvasive ventilation is recommended when the patient experiences orthopnea, nocturnal hypoxia, or a forced vital capacity (FVC) below 50%. Invasive ventilation may be considered if noninvasive ventilation is not tolerated or if the patient remains hypoxic or hypercarbic. Swallowing difficulties (dysphagia) are also common in ALS patients and should be managed initially with diet modifications. Enteral nutrition via percutaneous gastrostomy (G-tube) should be considered if the patient's oral intake is impaired, as weight loss is associated with a worse prognosis.
There are numerous complications associated with amyotrophic lateral sclerosis, including respiratory decline with eventual need for ventilatory support, dysphagia, dysarthria, malnutrition, spasms, spasticity, and fatigue, functional decline due to muscular weakness, sialorrhea, thick mucus secretions and pseudobulbar affect. In addition, some complications may arise due to the less-common medications meant to manage symptoms of the disease itself. These side effects include gastrointestinal upset and arrhythmias in mexiletine, transaminitis and asthenia in Riluzole, and gait disturbance and headache in edaravone.
""Amyotrophic Lateral Sclerosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Amyotrophic Lateral Sclerosis pipeline landscape is provided which includes the disease overview and Amyotrophic Lateral Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Amyotrophic Lateral Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Amyotrophic Lateral Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Amyotrophic Lateral Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Amyotrophic Lateral Sclerosis Emerging Drugs
Further product details are provided in the report……..
Amyotrophic Lateral Sclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Amyotrophic Lateral Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:
Amyotrophic Lateral Sclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Amyotrophic Lateral Sclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Amyotrophic Lateral Sclerosis drugs.
Amyotrophic Lateral Sclerosis Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 7-8 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Amyotrophic Lateral Sclerosis: Overview
Amyotrophic Lateral Sclerosis, also known as “Lou Gehrig disease,” is a neurodegenerative disease of the motor neurons. No single etiology has been proven; rather, multiple pathways (both heritable and sporadic) have been shown to result in unmistakably similar disease entities. ALS necessarily affects both upper and lower motor neurons with variable patterns of onset, most commonly beginning with signs of lower motor neuron degeneration within proximal limbs. As it is a progressive disease, it will eventually lead to paralysis and, inevitably, death.
Although many potential mechanisms have been proposed, a precise, single etiology of sporadic amyotrophic lateral sclerosis is yet unproven. These mechanisms include altered RNA processing leading to prion-like self-aggregation, superoxide dismutase type 1 SOD1 mutations leading to free radical toxicity, cascading inflammatory responses, and excessive concentrations of glutamate, among others. The rarer entity of familial ALS has numerous genetic mechanisms, most frequently repeat expansion of the C9ORF72 gene and various mutations of the SOD1 gene. Mutated SOD1 protein misfold and forms aggregates, leading to cellular injury and eventually apoptosis. Both genetic aberrations are inherited in a mainly autosomal dominant pattern. Ultimately, rather than a single unifying cause, ALS is an etiologically diverse clinical entity, which is the result of a multitude of separate potential preceding aberrations.
Respiratory management is crucial, as ALS patients often develop chronic respiratory failure due to weakening of the diaphragmatic and intercostal muscles. Noninvasive ventilation is recommended when the patient experiences orthopnea, nocturnal hypoxia, or a forced vital capacity (FVC) below 50%. Invasive ventilation may be considered if noninvasive ventilation is not tolerated or if the patient remains hypoxic or hypercarbic. Swallowing difficulties (dysphagia) are also common in ALS patients and should be managed initially with diet modifications. Enteral nutrition via percutaneous gastrostomy (G-tube) should be considered if the patient's oral intake is impaired, as weight loss is associated with a worse prognosis.
There are numerous complications associated with amyotrophic lateral sclerosis, including respiratory decline with eventual need for ventilatory support, dysphagia, dysarthria, malnutrition, spasms, spasticity, and fatigue, functional decline due to muscular weakness, sialorrhea, thick mucus secretions and pseudobulbar affect. In addition, some complications may arise due to the less-common medications meant to manage symptoms of the disease itself. These side effects include gastrointestinal upset and arrhythmias in mexiletine, transaminitis and asthenia in Riluzole, and gait disturbance and headache in edaravone.
""Amyotrophic Lateral Sclerosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Amyotrophic Lateral Sclerosis pipeline landscape is provided which includes the disease overview and Amyotrophic Lateral Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Amyotrophic Lateral Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Amyotrophic Lateral Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Amyotrophic Lateral Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Amyotrophic Lateral Sclerosis.
This segment of the Amyotrophic Lateral Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Amyotrophic Lateral Sclerosis Emerging Drugs
- MN-166: MediciNova
- RNS60: Revalesio
- VM202: Helixmith
- QRL-201: QurAlis Corporation
Further product details are provided in the report……..
Amyotrophic Lateral Sclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Amyotrophic Lateral Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Amyotrophic Lateral Sclerosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Amyotrophic Lateral Sclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Amyotrophic Lateral Sclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Amyotrophic Lateral Sclerosis drugs.
Amyotrophic Lateral Sclerosis Report Insights
- Amyotrophic Lateral Sclerosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Amyotrophic Lateral Sclerosis drugs?
- How many Amyotrophic Lateral Sclerosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Amyotrophic Lateral Sclerosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Amyotrophic Lateral Sclerosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Amyotrophic Lateral Sclerosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ionis Pharmaceuticals
- 1ST Biotherapeutics
- Scholar Rock
- Revalesio
- QurAlis Corporation
- Sanofi
- MediciNova
- Helixmith
- Verge Genomics
- UCB
- ION363
- FB418
- SRK-015
- RNS60
- QRL-201
- SAR443820
- MN-166
- VM202
- VRG-50635
- Zilucoplan
Please Note: It will take 7-8 business days to complete the report upon order confirmation.
Table of Contents
240 Pages
- Introduction
- Executive Summary
- Amyotrophic Lateral Sclerosis: Overview
- Etiology
- Pathophysiology
- Diagnosis
- Treatment and Management
- Complications
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Amyotrophic Lateral Sclerosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II/III)
- Comparative Analysis
- MN-166: MediciNova
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- QRL-201: QurAlis Corporation
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Amyotrophic Lateral Sclerosis Key Companies
- Amyotrophic Lateral Sclerosis Key Products
- Amyotrophic Lateral Sclerosis- Unmet Needs
- Amyotrophic Lateral Sclerosis- Market Drivers and Barriers
- Amyotrophic Lateral Sclerosis- Future Perspectives and Conclusion
- Amyotrophic Lateral Sclerosis Analyst Views
- Amyotrophic Lateral Sclerosis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.